Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients

American Journal of Hematology

Volumn 89, Issue 8, 2014, Pages 795-802

  Govindaraj, Chindu ^a   Madondo, Mutsa ^a   Kong, Ying Ying ^a   Tan, Peter ^b   Wei, Andrew ^b   Plebanski, Magdalena ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; GAMMA INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; TUMOR NECROSIS FACTOR RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; IMMUNOSURVEILLANCE; IN VITRO STUDY; LEUKEMIA REMISSION; LYMPHOCYTE FUNCTION; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE;

EID: 84904386072     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23746     Document Type: Article

References (45)

1. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine Dose for Acute Myeloid Leukemia. New Engl J Med 2011;364:1027-1036.
2. Bradstock KF, Matthews JP, Lowenthal RM, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481-488.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
4. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-4383.
5. Le Dieu R, Taussig DC, Ramsay AG, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009;114:3909-3916.
6. Wang X, Zheng J, Liu J, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005;75:468-476.
7. Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325-3332.
8. Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011;118:5084-5095.
9. Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011;129:1373-1381.
10. Curti A, Trabanelli S, Onofri C, et al. Indoleamine 2, 3-dioxygenase-expressing leukemic dendritic cells impair leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010;95:2022-2030.
11. Ge W, Ma X, Li X, et al. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leuk Res 2009;33:948-957.
12. Zhou Q, Munger ME, Highfill SL, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010;116:2484-2493.
13. Coles SJ, Hills RK, Wang EC, et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia 2012;26:2146-2148.
14. Quentmeier H, Dirks WG, Fleckenstein D, et al. Tumor necrosis factor-alpha-induced proliferation requires synthesis of granulocyte-macrophage colony-stimulating factor. Exp Hematol 2000;28:1008-1015.
15. Hamano R, Huang J, Yoshimura T, et al. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol 2011;41:2010-2020.
16. Elbaz O, Mahmoud LA. Tumor necrosis factor and human acute leukemia. Leuk Lymphoma 1994;12:191-195.
17. Chen X, Oppenheim JJ. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun 2010;11:119-134.
18. Kobari L, Weil D, Lemoine FM, et al. Secretion of tumor necrosis factor-alpha by fresh human acute nonlymphoblastic leukemic cells: role in the disappearance of normal CFU-GM progenitors. Exp Hematol 1990;18:1187-1192.
19. Chen X, Hamano R, Subleski JJ, et al. Expression of costimulatory TNFR2 induces resistance of CD4(+)FoxP3(-) conventional T cells to suppression by CD4(+)FoxP3(+) regulatory T Cells. J Immunol 2010;185:174-182.
20. Minigo G, Woodberry T, Piera KA, et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog 2009;5:e1000402.
21. Govindaraj C, Scalzo-Inguanti K, Madondo M, et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol 2013;149:97-110.
22. Chopra M, Riedel SS, Biehl M, et al. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 2013;34:1296-1303.
23. Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2012.
24. Prebet T, Charbonnier A, Gelsi-Boyer V, et al. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leuk Lymphoma 2012.
25. Lee BN, Gao H, Cohen EN, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011;117:3999-4008.
26. Chen Y, Borthakur G. Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opin Investig Drugs 2013;22:389-397.
27. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008;113:1605-1613.
28. Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005;75:485-491.
29. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702.
30. Platzbecker U, Germing U. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? Leukemia 2013;27:1813-1819.
31. Chen X, Subleski JJ, Hamano R, et al. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 2010;40:1099-1106.
32. Bontkes HJ, Ruben JM, Alhan C, et al. Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. Leuk Res 2012;36:921-930.
33. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011;117:1605-1613.
34. Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-1859.
35. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-386.
36. Chen X, Wu X, Zhou Q, et al. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol 2013;190:1076-1084.
37. Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012;119:3361-3369.
38. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-1045.
39. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9:1625-1630.
40. Marriott JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130:75-84.
41. Fischer R, Maier O, Naumer M, et al. Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFkappaB pathway. Cell Signal 2011;23:161-170.
42. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-167.
43. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
44. Payvandi F, Wu L, Naziruddin SD, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res 2005;25:604-616.
45. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203.